53. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents.

54. The pharmaceutical composition of claim 53 wherein the additional therapeutic agents are selected from the group consisting of CFTR modulators and CFTR amplifiers.

55. The pharmaceutical composition of claim 53 wherein the additional therapeutic agents are CFTR modulators.

56. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, one potentiator, and one or more correctors.

57. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents, in the manufacture of a medicament for treating cystic fibrosis in a subject.

58. The use of claim 57 wherein the additional therapeutic agents are selected from the group consisting of CFTR modulators and CFTR amplifiers.

59. The use of claim 57 the wherein the additional therapeutic agents are CFTR modulators.

60. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, one potentiator, and one or more correctors, in the manufacture of a medicament for treating cystic fibrosis in a subject.

61. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein the compound is 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl] carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid.

62. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein the compound is 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl] carbonyl}amino)-3,4-dihydro-2H-chromen-2-yl]benzoic acid.

63. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein the compound is 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl] carbonyl}amino)-6-methyl-3,4-dihydro-2H-chromen-2-yl]benzoic acid.

64. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein the compound is 3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl] carbonyl}amino)-6-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid.

65. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein the compound is *rac*-3-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl] carbonyl}amino)-7-methoxy-3,4-dihydro-2H-pyrano[2,3-b]pyridin-2-yl]benzoic acid.

66. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein the compound is 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl] carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]benzoic acid.

67. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein the compound is 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl] carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid.

68. The compound of claim 50 or a pharmaceutically acceptable salt thereof, wherein the compound is 4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl] carbonyl}amino)-7-methoxy-3,4-dihydro-2H-chromen-2-yl]-3-fluorobenzoic acid.